Apricus Biosciences

Apricus Bio (NASDAQ: APRI) is a San Diego-based biopharmaceutical company focused on the development of innovative drugs in the fields of urology and rheumatology. The company's first product, Vitaros®, has been approved in Europe and Canada and will be commercialized by Apricus' marketing partners, including Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox®, the company’s candidate product for the treatment of FSAID, has successfully completed a nearly 400-subject proof-of-concept study.